Table 1.

Study characteristics

First author	Year	Type of study	N	Grade of CIPN	Main types of antineoplastic drugs	Outcome measure	Type of cancer
Molassiotis A	2019 [24]	Cohort	255	≥ 1	Platinum, taxane	NCI-CTCAE	Breast, lung, ovarian, gastrointestinal, head & neck, and urinary tract cancers
Chen C	2019 [16]	Cohort	60	≥ 1	Oxaliplatin	WHO standard	Colorectal, gastric, and esophageal cancers
Hertz DL	2018 [25]	Cohort	60	Self-report	Cisplatin	EORTC QLQ-CIPN20	Breast cancer
Gaballah A	2018 [17]	Case–control	250	≥ 1	Platinum, taxane	NCI-CTCAE	NA
Yamaguchi K	2018 [26]	Cohort	60	≥ 2	Oxaliplatin	NCI-CTCAE	Gastric cancer
Dolan ME	2017 [27]	Cohort	680	Self-report	Cisplatin	EORTC QLQ-CIPN20	germ cell cancer
Song SJ	2017 [28]	Case–control	1516	≥ 2	Taxane	Cancer pain management guideline, 6th edition	Breast cancer
Hershman DL	2016 [23]	Case–control	1401	≥ 2	Multiple chemotherapy regimens	NCI-CTCAE	lung, prostate, breast, head and neck, bladder, and ovarian cancers
Bao T	2016 [29]	Case–control	296	≥ 1	Taxane	Cancer-related symptom rating scales	Breast cancer
Tanishima H	2016 [30]	Case–control	47	≥ 1	Oxaliplatin	NCI-CTCAE	Colorectal cancer
Pereira S	2016 [31]	Cohort	296	≥ 1	Taxane	NCI-CTCAE	Breast cancer
Wang YQ	2016 [18]	Case–control	225	≥ 2	Oxaliplatin, paclitaxel, vincristine	NCI-CTCAE	Colorectal, gastric, esophageal, lung, and ovarian cancers; lymphoma
Shahriari-Ahmadi A	2015 [32]	Case–control	130	≥ 1	Oxaliplatin	NCI-CTCAE	Colorectal cancer
Kus Ta	2015 [15]	Case–control	270	≥ 1	Taxane	NCI-CTCAE	NA
Kus Ta	2015 [15]	Case–control	104	≥ 1	Taxane, platinum	NCI-CTCAE	NA
de la Morena Barrio P	2015 [19]	Case–control	129	≥ 1	Paclitaxel	NCI-CTCAE	Breast cancer
Ding XF	2015 [20]	Cohort	94	≥ 1	Paclitaxel	Self-definition	Prostate, breast, ovarian, bladder, lung, and cervical cancers
Johnson Cb	2015 [21]	Case–control	735	≥ 1	Platinum, taxane	NCI-CTCAE	Lung cancer
Eckhoff L	2014 [33]	Cohort	150	≥ 2	Docetaxel	NCI-CTCAE	Breast cancer
Xue YJ	2013 [22]	Cohort	80	≥ 1	Paclitaxel	Levi	Breast, lung, esophageal, gastric, ovarian, and uterine cancers
Wang XY	2013 [34]	Case–control	171	≥ 2	Oxaliplatin	Levi	Colorectal cancer
Hashimoto N	2012 [35]	Case–control	48	≥ 2	Bortezomib	NCI-CTCAE	Multiple myeloma
Kawakami K	2012 [36]	Case–control	50	≥ 3	Paclitaxel, carboplatin	NCI-CTCAE	Non-small cell lung cancer
Vincenzi B	2012 [37]	Case–control	169	≥ 2	Oxaliplatin	NCI-CTCAE	Colorectal cancer
Uwah AN	2012 [38]	Case–control	62	≥ 2	Oxaliplatin	NCI-CTCAE	Colorectal cancer
Ramanathan RK	2010 [39]	Case–control	1585	≥ 1	Oxaliplatin	NCI-CTCAE, oxaliplatin-specific neurotoxicity scale	Colorectal cancer

NCI-CTCAE National Cancer Institute-Common Toxicity Criteria for Adverse Events; EORTC QLQ-CIPN20 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy; CIPN chemotherapy-induced peripheral neuropathy

^aThe incidence of CIPN was clearly distinguished between the two treatment schemes

^bPatients with unknown CIPN status were excluded from statistical analysis